New CDC Guidelines: People at Risk for HIV Should Consider Truvada PrEP

Healthcare providers should advise people at “substantial risk” for HIV infection about pre-exposure prophylaxis (PrEP) using tenofovir/emtricitabine, or Truvada, according to new guidelines issued by the U.S. Centers for Disease Control and Prevention (CDC). This includes HIV negative people in an ongoing sexual relationship with HIV positive partners, gay or bisexual men who have had sex without condoms during the past 6 months, heterosexual men and women who have sex without condoms with at-risk partners, and injection drug users.
The U.S. Food and Drug Administration (FDA) approved Truvada for PrEP in July 2012. Only Truvada taken every daily has been approved for HIV prevention. Taking it sporadically before sex or as a “morning after pill” has not been proven effective. HIV testing is important before starting PrEP, as a person who already has HIV and takes Truvada without other antiretrovirals could develop drug-resistant virus.
http://www.hivandhepatitis.com/hiv-prevention/hiv-prep/4689-new-cdc-guidelines-people-at-risk-for-hiv-should-consider-pre-exposure-prophylaxis-prep

PMMA-microspheres for the treatment of HIV-associated buttock lipodystrophy.

Soft tissue augmentation with PMMA-microspheres for the treatment of HIV-associated buttock lipodystrophy.

Authors

Serra MS, et al. 

Journal

Int J STD AIDS. 2014 May 22. pii: 0956462414536878. [Epub ahead of print]

Affiliation

Abstract

BACKGROUND: Progression of lipodystrophy syndrome is a big challenge in HIV treatment. Nowadays, fat loss at the lower part of buttocks has become another problem as patients started to complain that it is painful to be seated for a long time and/or on hard surfaces. We developed a method for buttock lipoatrophy treatment with PMMA-microspheres, as silicone prostheses and autologous fat transplant were not completely efficient.
METHODS: The treatment consisted of net-crossed injections, in the subcutaneous layer, of a 30% PMMA-microspheres solution on the atrophic areas of the buttock.
RESULTS: One hundred and fifty-four patients were included. The amount of PMMA-microspheres used to treat buttock lipoatrophy depended on the degree of atrophy and size of the area to be treated. Patients were satisfied with this treatment and referred to be more comfortable to be seated for longer period of time.
CONCLUSION: We demonstrated that soft tissue augmentation with PMMA-microspheres is safe and efficient for the treatment of buttock lipoatrophy associated with HIV lipodystrophy.
For more information on PMMA use for buttock lipoatrophy visit: http://facialwasting.org/buttock_wasting.htm